Human pre-formed anti-pig antibodies (XNA)

Human pre-formed anti-pig antibodies, also known as xenoreactive natural antibodies (XNAs), are immunoglobulins (predominantly IgM and some IgG) present in all humans that recognize porcine antigens without prior exposure. The primary target for these antibodies is the carbohydrate epitope galactose-alpha-1,3-galactose (alpha-Gal), which is synthesized by the enzyme alpha-1,3-galactosyltransferase in pigs but is absent in humans (Galili, 2013, PMC3841663). When porcine tissue or organs are transplanted into humans, these antibodies immediately bind to the donor vascular endothelium, triggering the classical complement pathway and resulting in hyperacute rejection (HAR) characterized by hemorrhage, edema, and graft failure within minutes (Lu et al., 2022, PMC8901310). In the context of xenotransplantation, these antibodies represent the most significant immunological barrier to successful graft survival. Clinical management involves reducing antibody titers through plasmapheresis or specialized immunoadsorption columns, alongside the use of immunosuppressants and complement inhibitors like eculizumab. Modern approaches also include the genetic modification of donor pigs to 'knock out' the GGTA1 gene, thereby eliminating the alpha-Gal antigen and preventing the initial binding of these pre-formed antibodies (Mohiuddin et al., 2016, PMC4832971).

Other names

Xenoreactive natural antibodiesAnti-alpha-galactosyl antibodiesAnti-Gal antibodiesHuman anti-pig antibodiesNatural xenoreactive antibodies

Therapeutic strategies involve the physical removal of these antibodies from the circulation via plasmapheresis or immunoadsorption, depletion of the B cells that produce them, or inhibition of the complement cascade (e.g., C5 inhibition) that is activated upon antibody binding to the porcine endothelium (Cooper et al., 2023, PMC10033102).